Ulisse Biomed Spa
MIL:UBM

Watchlist Manager
Ulisse Biomed Spa Logo
Ulisse Biomed Spa
MIL:UBM
Watchlist
Price: 0.798 EUR -0.25%
Market Cap: €20.4m

Operating Margin

-570.8%
Current
Improving
by 1 599.9%
vs 3-y average of -2 170.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-570.8%
=
Operating Income
€-5.3m
/
Revenue
€925.9k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-570.8%
=
Operating Income
€-5.3m
/
Revenue
€925.9k

Peer Comparison

Country Company Market Cap Operating
Margin
IT
Ulisse Biomed Spa
MIL:UBM
19.5m EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.2B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
166.3B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.9B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD
Loading...

Market Distribution

Lower than 99% of companies in Italy
Percentile
1st
Based on 1 199 companies
1st percentile
-570.8%
Low
-79 476% — 3.9%
Typical Range
3.9% — 14.4%
High
14.4% — 813.7%
Distribution Statistics
Italy
Min -79 476%
30th Percentile 3.9%
Median 8.7%
70th Percentile 14.4%
Max 813.7%

Ulisse Biomed Spa
Glance View

Market Cap
20.4m EUR
Industry
Biotechnology

Ulisse BioMed SpA is an Italian healthcare biotech company. The company is headquartered in Udine, Udine. The company went IPO on 2021-08-06. The firm focuses on creating new and transformative diagntostic platforms and products. The company creates diagnostic systems that can reach people directly and help increasing the frequency of health monitoring. Its platforms include Sagitta, NanoHybrid and Aptavir. Sagitta is a molecular diagnostics technology platform, capable of detecting and characterizing nucleic acids of viral, bacterial and eukaryotic origin. Sagitta is used to develop assays for Respiratory Viral Panel, Sexually Transmitted Diseases, Infectious Diseases and Oncology. NanoHybrid can be implemented not only to develop diagnostic solutions but also in the field of theranostics: the integration of a diagnostic method with a specific therapeutic intervention aimed at maximizing the effectiveness of the drug, as well as vaccine/immunoterapies monitoring. Aptavir is a platform for the identification and production of antiviral molecules.

UBM Intrinsic Value
1.744 EUR
Undervaluation 54%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-570.8%
=
Operating Income
€-5.3m
/
Revenue
€925.9k
What is Ulisse Biomed Spa's current Operating Margin?

The current Operating Margin for Ulisse Biomed Spa is -570.8%, which is above its 3-year median of -2 170.7%.

How has Operating Margin changed over time?

Over the last 3 years, Ulisse Biomed Spa’s Operating Margin has decreased from -537.5% to -570.8%. During this period, it reached a low of -7 245.5% on Dec 31, 2023 and a high of -537.5% on May 30, 2022.

Back to Top